Moves are under way in France to give the biosimilars market a shot in the arm by setting a 70% target for initial prescribing rates and encouraging pharmacist substitution through the creation of similar biological medicine groups.

Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.

The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.